Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND & AIMS">Regulatory T cell (Treg) depletion increases antitumor immunity. However, severe autoimmunity can occur following systemic loss of Tregs, which could be avoided by selectively depleting intratumoral Tregs. Herein, we aimed to investigate the role of tumor-infiltrating CCR4+ Tregs in hepatocellular carcinoma (HCC) and to provide a potential target strategy for immunotherapy.</AbstractText>METHODS: <AbstractText Label="METHODS">CCR4+ Tregs were analyzed by flow cytometry in murine models and clinical samples. The function of tumor-infiltrating and induced CCR4+ Tregs was interrogated by genetic and epigenetic approaches. To block CCR4+ Treg chemotaxis, we developed an N-terminus recombinant protein of CCR4 (N-CCR4-Fc) as a neutralizing pseudo-receptor that effectively bound to its ligand CCL22. The efficacy of CCR4 antagonism as an immunotherapeutic agent was evaluated by tumor weights, growth kinetics and survival curves.</AbstractText>RESULTS: <AbstractText Label="RESULTS">CCR4+ Tregs were the predominant type of Tregs recruited to hepatitis B-associated HCC (HBV+ HCC), correlating with sorafenib resistance and HBV load titers. Compared with CCR4- Tregs, CCR4+ Tregs exhibited increased IL-10 and IL-35 expression, and enhanced functionality in suppressing CD8+ T cells. CCR4+ Tregs also displayed PD-1+TCF1+ stem-like properties. ATAC-seq data revealed substantial chromatin remodeling between tumor-infiltrating Tregs (TIL-Tregs) and induced Tregs, suggesting that long-term chromatin reprogramming accounted for the acquisition of enhanced immunosuppressive stem-like specificity by CCR4+ TIL-Tregs. Treatment with a CCR4 antagonist or N-CCR4-Fc blocked intratumoral Treg accumulation, overcame sorafenib resistance, and sensitized tumors to PD-1 checkpoint blockade.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">Intratumoral stem-like CCR4+ Tregs orchestrated immunosuppressive resource cells in the tumor microenvironment. CCR4 could be targeted to enhance antitumor immunity by specifically blocking infiltration of Tregs into the tumor microenvironment and inhibiting maintenance of the TIL-Treg pool.</AbstractText>LAY SUMMARY: <AbstractText Label="LAY SUMMARY">Targeting regulatory T cells is a promising approach in cancer immunotherapy; however, severe autoimmunity can occur following systemic regulatory T cell loss. This could be avoided by selectively depleting intratumoral regulatory T cells. Herein, targeting intratumoral stem-like CCR4+ regulatory T cells helped to overcome sorafenib resistance and sensitize tumors to immune checkpoint blockade in mouse models of liver cancer. This approach could have wide clinical applicability.</AbstractText>

Liver-specific T regulatory type-1 cells program local neutrophils to suppress hepatic autoimmunity via CRAMP

Ubiquitous Antigen-Specific T Regulatory Type 1 Cells Variably Suppress Hepatic and Extrahepatic Autoimmunity.

Impact of Regulatory T Cells on Innate Immune Cells in a Pre-Sensitized Heart Transplant Model

Re-programming mouse liver-resident invariant natural killer T cells for suppressing hepatic and diabetogenic autoimmunity

Hepatic overexpression of cAMP-responsive element modulator α induces a regulatory T-cell response in a murine model of chronic liver disease

Activation of AMPKα1 is essential for regulatory T cell function and autoimmune liver disease prevention

Engaging natural regulatory myeloid cells to restrict T-cell hyperactivation-induced liver inflammation via extracellular vesicle-mediated purine metabolism regulation

Suppression of a Broad Spectrum of Liver Autoimmune Pathologies by Single Peptide-Mhc-based Nanomedicines

Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer

Regulatory T cells control type 1-driven immunopathology restraining GM-CSF-producing helper T cells

A pathogenic role for regulatory T cells in chronic liver disease

Single-Target Pan-Liver Autoimmune Disease-Suppressing Nanomedicines

Immune Homeostasis Enforced by Co-Localized Effector and Regulatory T Cells

Hepatic Regulatory T-cells Promote Colorectal Liver Metastasis in NASH

Suppression of lethal autoimmunity by regulatory T cells with a single TCR specificity

Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis.

Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B

Selective regulation of IFN-γ and IL-4 co-producing unconventional T cells by purinergic signalling

Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific.

CAR directs T cell adaptation to bile acids in the small intestine

Liver-resident NK Cells Suppress Autoimmune Cholangitis and Limit the Proliferation of CD4+ T Cells